Schedule 13G ownership disclosure

Monte Rosa Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 61225M102

Event date: 2025-10-10

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • TCG Crossover GP II, LLC

    Shares: 2,213,853 · Class: 3.6%

  • TCG Crossover Fund II, L.P.

    Shares: 2,213,853 · Class: 3.6%

  • TCG Crossover GP III, LLC

    Shares: 2,213,852 · Class: 3.6%

  • TCG Crossover Fund III, L.P.

    Shares: 2,213,852 · Class: 3.6%

  • Chen Yu

    Shares: 4,427,705 · Class: 7.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-25-242555
Form type
SCHEDULE 13G
Filer
Monte Rosa Therapeutics, Inc.
CIK
CIK 1826457
Filed
Oct 17, 2025
Reporting period
Oct 10, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub